Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Monoisotopic mass
284.071640755
InChI
InChI=1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2
InChI Key
InChIKey=ZPXSCAKFGYXMGA-UHFFFAOYSA-N
IUPAC Name
5-(4-chlorophenyl)-2H,3H,5H-imidazo[2,1-a]isoindol-5-ol
Traditional IUPAC Name
mazindol
SMILES
OC1(N2CCN=C2C2=CC=CC=C12)C1=CC=C(Cl)C=C1
pKa (strongest acidic)
11.61
pKa (Strongest Basic)
3.86
Refractivity
79.42 m3·mol-1
Dược Lực Học :
Mazindol is a sympathomimetic amine, which is similar to an amphetamine. Mazindol stimulates the central nervous system (nerves and brain), which increases your heart rate and blood pressure and decreases your appetite. Sympathomimetic appetite suppressants are used in the short-term treatment of obesity. Their appetite-reducing effect tends to decrease after a few weeks. Because of this, these medicines are useful only during the first few weeks of a weight-loss program.
Cơ Chế Tác Dụng :
Mazindol is a tricyclic anorexigenic agent unrelated to and less toxic than amphetamine, but with some similar side effects. It inhibits uptake of catecholamines and blocks the binding of cocaine to the dopamine uptake transporter. Mazindol is only approved in the United States for the treatment of Duchenne muscular dystrophy, and is not marketed or available in the United States for use in the treatment of obesity.
Although the mechanism of action of the sympathomimetics in the treatment of obesity is not fully known, these medications have pharmacological effects similar to those of amphetamines. Unlike other sympathomimetic appetite suppressants such as phentermine, mazindol is thought to inhibit the reuptake of norepinephrine rather than to cause its release.
Dược Động Học :
▧ Metabolism :
Hepatic.
▧ Half Life :
10-13 hours
Độc Tính :
Symptoms of a mazindol overdose include restlessness, tremor, rapid breathing, confusion, hallucinations, panic, aggressiveness, nausea, vomiting, diarrhea, an irregular heartbeat, and seizures.
Chỉ Định :
Used in short-term (a few weeks) treatment of exogenous obesity in conjunction with a regimen of weight reduction based on caloric restriction, exercise, and behavior modification in patients with a body mass index of 30 kg of body weight per height in meters squared (kg/m2) or in patients with a body mass index of 27 kg/m2 in the presence of risk factors such as hypertension, diabetes, or hyperlipidemia.
Tương Tác Thuốc :
-
Acetophenazine
Decreased anorexic effect, may increase psychotic symptoms
-
Alimemazine
Decreased anorexic effect, may increase psychotic symptoms
-
Chlorpromazine
Decreased anorexic effect, may increase psychotic symptoms
-
Ethopropazine
Decreased anorexic effect, may increase psychotic symptoms
-
Fluoxetine
Risk of serotoninergic syndrome
-
Fluphenazine
Decreased anorexic effect, may increase psychotic symptoms
-
Fluvoxamine
Risk of serotoninergic syndrome
-
Guanethidine
Mazindol may decrease the effect of guanethidine.
-
Isocarboxazid
Possible hypertensive crisis
-
Mesoridazine
Decreased anorexic effect, may increase psychotic symptoms
-
Methdilazine
Decreased anorexic effect, may increase psychotic symptoms
-
Methotrimeprazine
Decreased anorexic effect, may increase psychotic symptoms
-
Paroxetine
Risk of serotoninergic syndrome
-
Perphenazine
Decreased anorexic effect, may increase psychotic symptoms
-
Phenelzine
Possible hypertensive crisis
-
Prochlorperazine
Decreased anorexic effect, may increase psychotic symptoms.
-
Promazine
Decreased anorexic effect, may increase psychotic symptoms
-
Promethazine
Decreased anorexic effect, may increase psychotic symptoms.
-
Propericiazine
Decreased anorexic effect, may increase psychotic symptoms.
-
Propiomazine
Decreased anorexic effect, may increase psychotic symptoms
-
Rasagiline
Possible hypertensive crisis
-
Thiethylperazine
Decreased anorexic effect, may increase psychotic symptoms
-
Thioridazine
Decreased anorexic effect, may increase psychotic symptoms
-
Tranylcypromine
Possible hypertensive crisis
-
Trifluoperazine
Decreased anorexic effect, may increase psychotic symptoms
-
Triflupromazine
Decreased anorexic effect, may increase psychotic symptoms
-
Venlafaxine
Risk of serotoninergic syndrome
Dữ Kiện Thương Mại
Nhà Sản Xuất
-
Sản phẩm biệt dược : Dimagrir
-
Sản phẩm biệt dược : Fagolip Plus
-
Sản phẩm biệt dược : Mazanor
-
Sản phẩm biệt dược : Sanorex
-
Sản phẩm biệt dược : Teronac